Canada - English - Health Canada

lupin pharma canada limited - estradiol (estradiol hemihydrate) - tablet - 2mg - estradiol (estradiol hemihydrate) 2mg - estrogens

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - estradiol hemihydrate (unii: cxy7b3q98z) (estradiol - unii:4ti98z838e) - estradiol 10 ug - yuvafem should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known anaphylactic reaction or angioedema to  yuvafem - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy yuvafem should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. yuvafem should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast m

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol hemihydrate, quantity: 2.06 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: maize starch; hypromellose; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised post menopausal women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use. in women with an intact uteri, use of opposed therapy must be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - estradiol hemihydrate, quantity: 2 mg - drug delivery system, vaginal - excipient ingredients: polysilicone-11; barium sulfate; steareth-2; simethicone; sorbic acid - treatment for atrophic vaginitis (due to estrogen deficiency) in post-menopausal women

Malta - English - Medicines Authority

gedeon richter plc gyomroi ut 19-21 1103 budapest, hungary - estradiol hemihydrate - vaginal tablet - estradiol hemihydrate 10 µg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: hypromellose; lactose monohydrate; magnesium stearate; maize starch; macrogol 6000 - estro-pess is indicated for the treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women.,estro-pess is not intended for children or males.

New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - estradiol hemihydrate 150ug;  ;   - nasal spray solution - 150 mcg/dose - active: estradiol hemihydrate 150ug     excipient: hydrochloric acid purified water randomly methylated beta-cyclodextrin sodium chloride sodium hydroxide

Israel - English - Ministry of Health

j-c health care ltd - estradiol as hemihydrate; estradiol as hemihydrate; norethisterone acetate - patches - estradiol as hemihydrate 3.2 mg; norethisterone acetate 11.2 mg; estradiol as hemihydrate 3.2 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy for the relief of menopausal symptoms.

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for decreasing the risk of postmenop